91 related articles for article (PubMed ID: 3061927)
1. [Approaches to developing an optimal vaccine against hepatitis B viruses].
Gerlich WH; Heermann KH; Thomssen R
Immun Infekt; 1988 Oct; 16(5):167-74. PubMed ID: 3061927
[TBL] [Abstract][Full Text] [Related]
2. Interactions of hepatitis B virus with hepatocytes: mechanism and clinical relevance.
Theilmann L; Goeser T
Hepatogastroenterology; 1991 Feb; 38(1):10-3. PubMed ID: 1709133
[TBL] [Abstract][Full Text] [Related]
3. [Antibody responses in human being to pre-S2 and related hepatitis B virus-envelope antigens in vivo and in vitro].
Ogata M; Ishikawa H; Kato Y; Honta S; Yoshida H; Yasuda H; Ohto H; Watanabe N
Rinsho Byori; 1991 Jan; 39(1):3-13. PubMed ID: 1826138
[TBL] [Abstract][Full Text] [Related]
4. Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine.
Beaumont E; Patient R; Hourioux C; Dimier-Poisson I; Roingeard P
Hepatology; 2013 Apr; 57(4):1303-13. PubMed ID: 23150224
[TBL] [Abstract][Full Text] [Related]
5. [H-B-VAX II hepatitis B vaccine (recombinant) produced at the MSD Research Laboratories. Description of the vaccine].
Przegl Epidemiol; 1991; 45(1-2):3-10. PubMed ID: 1839076
[No Abstract] [Full Text] [Related]
6. [The impact of hepatitis B vaccination in Italy and the advent of novel recombinant vaccines containing pre-S1 and pre-S2].
Romanò L; Biffi R; Bianchi S; Zanetti A
Ann Ig; 2002; 14(3 Suppl 3):19-25. PubMed ID: 12389407
[No Abstract] [Full Text] [Related]
7. The preS1 antigen of hepatitis B virus is highly immunogenic at the T cell level in man.
Ferrari C; Penna A; Bertoletti A; Cavalli A; Valli A; Schianchi C; Fiaccadori F
J Clin Invest; 1989 Oct; 84(4):1314-9. PubMed ID: 2529268
[TBL] [Abstract][Full Text] [Related]
8. The immune response to hepatitis B virus.
Waters JA; Pignatelli M; Brown D; O'Rourke S; Lever A; Thomas HC
Postgrad Med J; 1987; 63 Suppl 2():51-6. PubMed ID: 2446303
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms.
Ho JK; Jeevan-Raj B; Netter HJ
Viruses; 2020 Jan; 12(2):. PubMed ID: 31973017
[No Abstract] [Full Text] [Related]
10. Immune responses to recombinant Mycobacterium smegmatis expressing fused core protein and preS1 peptide of hepatitis B virus in mice.
Yue Q; Hu X; Yin W; Xu X; Wei S; Lei Y; Lü X; Yang J; Su M; Xu Z; Hao X
J Virol Methods; 2007 Apr; 141(1):41-8. PubMed ID: 17197041
[TBL] [Abstract][Full Text] [Related]
11. [Detection of pre-S gene products in HBsAg carriers and in hepatitis B vaccines].
Gerken G; Manns M; Kyriatsoulis A; Hess G; Meyer zum Büschenfelde KH
Z Gastroenterol; 1988 Jul; 26(7):374-9. PubMed ID: 2851893
[TBL] [Abstract][Full Text] [Related]
12. Use of conventional or replicating nucleic acid-based vaccines and recombinant Semliki forest virus-derived particles for the induction of immune responses against hepatitis C virus core and E2 antigens.
Vidalin O; Fournillier A; Renard N; Chen M; Depla E; Boucreux D; Brinster C; Baumert T; Nakano I; Fukuda Y; Liljeström P; Trépo C; Inchauspé G
Virology; 2000 Oct; 276(2):259-70. PubMed ID: 11040118
[TBL] [Abstract][Full Text] [Related]
13. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.
Vietheer PT; Boo I; Drummer HE; Netter HJ
Antivir Ther; 2007; 12(4):477-87. PubMed ID: 17668556
[TBL] [Abstract][Full Text] [Related]
14. In vitro T cell immune responses to the preS2 antigen of the hepatitis B virus envelope protein in preS2 + S vaccine recipients. Absence of cross-reactivity of subtypes at a major T cell recognition site.
Cupps TR; Tibbles J; Hurni WM; Miller WJ; Ellis RW; Milich D; Wetter N
J Immunol; 1993 Sep; 151(6):3353-60. PubMed ID: 7690803
[TBL] [Abstract][Full Text] [Related]
15. Developments in immunization against hepatitis B.
Zuckerman AJ
Ann Ist Super Sanita; 1987; 24(2):285-91. PubMed ID: 2969206
[No Abstract] [Full Text] [Related]
16. Immunoreactivity of HCV/HBV epitopes displayed in an epitope-presenting system.
Chen Y; Xiong X; Liu X; Li J; Wen Y; Chen Y; Dai Q; Cao Z; Yu W
Mol Immunol; 2006 Feb; 43(5):436-42. PubMed ID: 16337486
[TBL] [Abstract][Full Text] [Related]
17. Protective effect of a synthetic peptide comprising the complete preS2 region of the hepatitis B virus surface protein.
Emini EA; Larson V; Eichberg J; Conard P; Garsky VM; Lee DR; Ellis RW; Miller WJ; Anderson CA; Gerety RJ
J Med Virol; 1989 May; 28(1):7-12. PubMed ID: 2723618
[TBL] [Abstract][Full Text] [Related]
18. [Active preventive vaccination against hepatitis B].
Jilg W
Internist (Berl); 1985 Oct; 26(10):633-9. PubMed ID: 2934346
[No Abstract] [Full Text] [Related]
19. Immunological response to pre-S antigens of the hepatitis B virus.
Milich DR
Viral Immunol; 1987; 1(2):83-96. PubMed ID: 3334703
[No Abstract] [Full Text] [Related]
20. [Enhancement of cellular immune response to DNA vaccine encoding hepatitis C virus core and envelope 2 fusion antigen by murine Fms-like tyrosine kinase 3 ligand].
Ke JS; Zhao P; Cao J; Yu JP; Qi ZT
Sheng Wu Gong Cheng Xue Bao; 2003 Mar; 19(2):158-62. PubMed ID: 15966314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
